Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Kazakhstan (1)
Lithuania (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Russia (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Uzbekistan (1)
STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG
STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.
STADA Arzneimittel AG and Ladival GmbH & Co KG have agreed to transfer the rights for the sunscreen Ladival back to the German pharmaceu…
Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…
STADA continues to advance its strategic reorientation.
STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.
STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…
STADA is systematically pushing ahead with the new strategy announced in March.
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology
At the press conference on March 8, 2018 STADA CEO Dr. Claudio Albrecht presented his vision for STADA and the company’s new strategy. In th…
The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…
STADA is advancing the internationalization of its OTC brand business.